Geoffrey J. Maher
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Demographics of epithelioid trophoblastic tumour and placental site trophoblastic tumour: a 21 year UK population study.
Journal: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
Published: October 16, 2025
Primary Uterine Nongestational Placental Site Trophoblastic Tumor as a Distinct Entity: A Report of 5 Cases.
Journal: The American journal of surgical pathology
Published: June 10, 2025
Monitoring complete hydatidiform molar pregnancies after normalisation of human chorionic gonadotrophin: national retrospective population study.
Journal: BMJ medicine
Published: July 11, 2024
Correction to: Practical guidelines of the EOTTD for pathological and genetic diagnosis of hydatidiform moles.
Journal: Virchows Archiv : an international journal of pathology
Published: February 29, 2024
Morphology combined with HER2 D-DISH ploidy analysis to diagnose partial hydatidiform mole: an evaluation audit using molecular genotyping.
Journal: Journal of clinical pathology
Published: November 04, 2023
Practical guidelines of the EOTTD for pathological and genetic diagnosis of hydatidiform moles.
Journal: Virchows Archiv : an international journal of pathology
Published: June 26, 2023
Defects in meiosis I contribute to the genesis of androgenetic hydatidiform moles.
Journal: The Journal of clinical investigation
Published: March 21, 2023
When to Consult a Geneticist Specialising in Gestational Trophoblastic Disease.
Journal: Gynecologic and obstetric investigation
Published: February 01, 2023
Personalized recurrence risk assessment following the birth of a child with a pathogenic de novo mutation.
Journal: Nature communications
Published: October 31, 2022
Epithelioid trophoblastic tumor with antecedent molar pregnancy in an HIV-positive patient.
Journal: Clinical case reports
Published: August 02, 2022
Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
Journal: Oncogene
Published: May 31, 2022
Last Updated: 09/26/2026